Pharnext: fundraising, new trading calendar
The biopharmaceutical company states that the OCABSA issue has enabled it to raise a total of 39.2 million euros, via the creation of 29.8 billion new shares.
The interest of a shareholder holding 1% of the capital prior to these drawdowns is now less than 0.0007%.
On Monday, Pharnext also announced a new timetable for negotiations aimed at increasing the value of its drug candidate for Charcot-Marie-Tooth type 1A disease.
Given the proximity of the first results from the pivotal Phase III
clinical study, scheduled for December 11, the company - which has received three offers to date - has decided not to sign an exclusivity agreement at this stage.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction